# Geron Corp (GERN)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/geron-corp/ JSON: https://steadybase.io/company/geron-corp.json Checked Nov 21, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: GERON CORP
- Ticker: GERN (Nasdaq)
- SEC CIK: 0000886744
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Foster City, CA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: geron.com
- LinkedIn: https://www.linkedin.com/company/geron
- Next earnings date: Feb 3, 2027

## Key facts

- Revenue: $237,000 for the fiscal year ended Dec 31, 2023 (10-K filed Feb 28, 2024). Source: https://www.sec.gov/Archives/edgar/data/886744/000095017024022056/0000950170-24-022056-index.html
- Operating income: -$68.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/0000886744-26-000008-index.html
- Net income: -$83.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/0000886744-26-000008-index.html
- SG&A: $159.3M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 2, 2026). Source: https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/0000886744-26-000008-index.html
- Employees: 258 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/gern-20251231.htm
- Shares outstanding: 644,238,859 as of Oct 30, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/886744/000088674426000041/0000886744-26-000041-index.html
- Auditor: Ernst & Young LLP, Iselin, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/gern-20251231.htm

## Business

Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO ® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California.

Source: Press release "About" paragraph, https://www.sec.gov/Archives/edgar/data/886744/000119312526436272/d43013dex991.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2023 | $237,000 | -$193.9M | -$184.1M | $69.1M |
| Dec 31, 2022 | $596,000 | -$138.6M | -$141.9M | $43.6M |
| Dec 31, 2021 | $1.4M | -$114.0M | -$116.1M | $29.7M |
| Dec 31, 2020 | $253,000 | n/a | n/a | n/a |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/geron-corp.json

## Officers and directors

- Harout Semerjian, President & CEO. Source: Form 4 filed Nov 16, 2026, https://www.sec.gov/Archives/edgar/data/886744/000180974726000002/0001809747-26-000002-index.htm
- Michelle Robertson, EVP, CHIEF FINANCIAL OFFICER. Source: Form 4 filed Feb 19, 2026, https://www.sec.gov/Archives/edgar/data/886744/000175509826000001/0001755098-26-000001-index.htm
- Timothy Williams, EVP and Chief Legal Officer. Source: Form 4 filed Apr 14, 2026, https://www.sec.gov/Archives/edgar/data/886744/000174839226000005/0001748392-26-000005-index.htm
- Ahmed ElNawawi, Executive Vice President, Chief Commercial Officer. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/gern-20251231.htm
- Joseph Eid, Executive Vice President Research and Development. Source: 10-K filed Mar 2, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/gern-20251231.htm
- Andrew J. Grethlein, Ph.D., Named in proxy. Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- Constantine Chinoporos, Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- Dawn C. Bir, Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- Elizabeth G. O'Farrell, Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- James Ziegler, Named in proxy. Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- John A. Scarlett, M.D., Named in proxy. Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- John F. McDonald, Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- Joseph Eid, M.D., Named in proxy. Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- Michelle J. Robertson, Named in proxy. Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- Patricia S. Andrews, Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- Robert J. Spiegel, M.D., FACP, Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- Susan M. Molineaux, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm
- V. Bryan Lawlis, Ph.D., Board member (per proxy). Source: DEF 14A filed Apr 7, 2026, https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm

## Recent 8-K events

- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/886744/000119312526446203/d188608d8k.htm
- Oct 28, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/886744/000119312526436272/d43013d8k.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/886744/000119312526336508/d158179d8k.htm
- May 27, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/886744/000119312526241842/d76653d8k.htm
- Mar 26, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/886744/000119312526125151/d192220d8k.htm
- Feb 25, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/886744/000119312526068523/d67820d8k.htm
- Jan 12, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/886744/000088674426000003/gern-20260112.htm
- Jan 6, 2026: Item 1.01, Entry into a material definitive agreement. Source: https://www.sec.gov/Archives/edgar/data/886744/000119312526003388/d88250d8k.htm
- Dec 16, 2025: Item 2.05, Costs associated with exit or disposal activities (restructuring). Source: https://www.sec.gov/Archives/edgar/data/886744/000088674425000074/gern-20251210.htm
- Nov 5, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/886744/000088674425000068/gern-20251105.htm

## Insider trades (Form 4)

- Nov 16, 2026: Timothy Williams (EVP and Chief Legal Officer) bought 12,000 shares, about $11,280. Source: https://www.sec.gov/Archives/edgar/data/886744/000174839226000007/0001748392-26-000007-index.htm
- Nov 13, 2026: Harout Semerjian (President & CEO) bought 53,500 shares, about $50,825. Source: https://www.sec.gov/Archives/edgar/data/886744/000180974726000002/0001809747-26-000002-index.htm
- Feb 18, 2026: Michelle Robertson (EVP, CHIEF FINANCIAL OFFICER) sold 9,855 shares, about $19,119. Source: https://www.sec.gov/Archives/edgar/data/886744/000175509826000001/0001755098-26-000001-index.htm

## What management said

- "Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S." Harout Semerjian, President and Chief Executive Officer of Geron (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/886744/000119312526446203/d188608dex991.htm

## Latest filings

- 8-K filed Oct 28, 2026: https://www.sec.gov/Archives/edgar/data/886744/000119312526436272/d43013d8k.htm
- 10-K filed Mar 2, 2026: https://www.sec.gov/Archives/edgar/data/886744/000088674426000008/gern-20251231.htm
- 10-Q filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/886744/000088674426000037/gern-20260630.htm
- DEF 14A filed Apr 7, 2026: https://www.sec.gov/Archives/edgar/data/886744/000088674426000024/gern-20260407.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

